Investigation on the individualized starting dose of 6-mercaptopurine based on pharmacogenetics

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

CRIS

Registry ID

KCT0006822

Enrollment

Registered

2021-12-09

Start date

2019-07-03

Completion date

Unknown

Last updated

2022-01-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : In patients undergoing maintenance therapy for pediatric acute lymphoblastic leukemia, the daily dose of 6-mercaptopurine was adjusted according to the pharmacogenetic analysis as 50g/m2 (both

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. 1 year < age < 21 years old 2. Newly diagnosed pediatric acute lymphoblastic leukemia patients who achieved complete remission through remission induction therapy 3. Patients who have pharmacogenetics results and start maintenance therapy

Exclusion criteria

Exclusion criteria: 1. Patients who plan to undergo hematopoietic stem cell transplantation 2. Patients who have relapsed

Design outcomes

Primary

Measure	Time frame
Total duration of treatment discontinuation during maintenance therapy	—

Secondary

Measure	Time frame
Frequency of neutropenia (ANC <500) during maintenance therapy/Percentage of neutropenic fever during maintenance therapy/Relapsed rate	—

Countries

Korea, Republic of

Contacts

Public ContactHyery Kim

Asan Medical Center

taban@hanmail.net+82-2-3010-3373

Outcome results